As of June 30, the company had cash and cash equivalents of approximately $33.4M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio Completes Phase I/II Trial for INKmune™
- INmune Bio options imply 16.2% move in share price post-earnings
- Largest borrow rate increases among liquid names
- INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
- INmune Bio options imply 14.9% move in share price post-earnings